Brief: Enanta Pharmaceuticals Reports Positive Results From Phase 2 Sprint Trial Evaluating EDP-235 In Standard Risk Patients With Covid-19

Enanta Pharmaceuticals

08/05/2023 22:19

May 8 (Reuters) - Enanta Pharmaceuticals Inc  ENTA.O :
    * ENANTA PHARMACEUTICALS REPORTS POSITIVE TOPLINE RESULTS
FROM
PHASE 2 SPRINT TRIAL EVALUATING EDP-235 IN STANDARD RISK
PATIENTS WITH COVID-19
    * ENANTA PHARMACEUTICALS INC - STUDY MET PRIMARY ENDPOINTS
OF
SAFETY AND TOLERABILITY
    * ENANTA PHARMACEUTICALS INC - TRIAL SHOWED NO DIFFERENCE IN
VIRAL
LOAD REDUCTION; RAPID DECLINE OBSERVED IN ALL STUDY ARMS
    * ENANTA PHARMACEUTICALS INC - TRIAL SHOWED DOSE-DEPENDENT
IMPROVEMENT IN TOTAL SYMPTOM SCORE OBSERVED WITH EDP-235
TREATMENT COMPARED TO PLACEBO

Source text for Eikon:  ID:nBw6KqFCGa 
Further company coverage:  ENTA.O 

 ((Reutersbriefs@thomsonreuters.com;))